The global colostrum market is entering a value-driven growth phase as demand shifts toward standardized, high-bioactive ...

At the 2026 BiOS conference in San Francisco, researchers presented a biosensing platform aimed at improving how living cells and tissues are monitored during drug bioprocessing. Known as TissueSense, ...

Southern California has had a flurry of activity—from investments by major companies to acquisitions and an IPO—over the past ...

State Street SPDR S&P Biotech ETF (XBI) gained +40.32% over the past year and equally weights roughly 145 stocks to provide exposure to smaller biotech companies. iShares Biotechnology ETF (IBB) ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the figures. According to an analysis of Fierce Biotech’s layoff data, a total ...

Novartis' acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company's existing allergy portfolio. It comes just a week after Novartis announced it is acquiring ...

Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

A handful of antibody-based extracellular targeted protein degraders are advancing in the clinic, highlighting emerging ...

U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists ...

A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.